EUCTR2005-005335-94-ES进行中（未招募）不适用
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOLProtocolo de continuación de tratamiento para pacientes provenientes de un protocolo previo con SU011248
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer, S.A.
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Partecipated ina previous SU011248 protocol and are judged by the investigator
- •to have the potential to derive clinical benefit from SU011248 treatment
- •2. Signed and dated informed consent document indicating that the patient (or
- •legally acceptable representative) has been informed of all the pertinent aspects
- •of the trial prior to enrollment.
- •3. Enrollment within 8 weeks from their last dose of SU011248 or placebo in their
- •previous study.
- •4. Willingness and ability to comply with scheduled visits, treatment plans and
- •laboratory tests and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following will not be included in the trial:
- •1. Current treatment in another clinical trial
- •2. Pregnancy or breastfeeding
- •3. Severe acute or chronic medical or psychiatric condition, or laboratory
- •abnormality that would impart, in the judgment of the investigator, excess risk
- •associated with study participation or study drug administration, or which, in the
- •judgment of the investigator, would make the patient inappropriate for entry
- •into this study
研究者
相似试验
进行中（未招募）
不适用
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOPatients with any malignancy who have previously been evaluated in a SU011248 protocolEUCTR2005-005335-94-DEPfizer Pharma GmbH300
进行中（未招募）
1 期
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOPatients with any malignancy who have previously been evaluated in a SU001248 protocolEUCTR2005-005335-94-NLPfizer BV
进行中（未招募）
1 期
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIORSU011248 PROTOCOEUCTR2005-005335-94-FRPfizer Inc.300
进行中（未招募）
不适用
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOL - NDPatients with any malignancy who have previously been evaluated in a SU011248 protocolMedDRA version: 9.1Level: LLTClassification code 10028997Term: Neoplasm malignantEUCTR2005-005335-94-ITPFIZER500
进行中（未招募）
不适用
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001093-11-SEPfizer Ltd